Lauren N Bowen1, Richa Tyagi1, Wenxue Li1, Tariq Alfahad1, Bryan Smith1, Mary Wright1, Elyse J Singer1, Avindra Nath2. 1. From the Section of Infections of the Nervous System, National Institute of Neurological Diseases and Stroke (L.N.B., R.T., W.L., T.A., B.S., A.N.), and National Institute of Allergy and Infectious Diseases (M.W.), NIH, Bethesda, MD; and National Neurological AIDS Bank and Department of Neurology (E.J.S.), University of California, Los Angeles. 2. From the Section of Infections of the Nervous System, National Institute of Neurological Diseases and Stroke (L.N.B., R.T., W.L., T.A., B.S., A.N.), and National Institute of Allergy and Infectious Diseases (M.W.), NIH, Bethesda, MD; and National Neurological AIDS Bank and Department of Neurology (E.J.S.), University of California, Los Angeles. natha@ninds.nih.gov.
Abstract
OBJECTIVE: To determine whether there is activation of human endogenous retrovirus K (HERV-K) in amyotrophic lateral sclerosis in HIV infection and whether it might respond to treatment with antiretroviral drugs. METHODS: In this case series, we present 5 patients with HIV infection who subsequently developed motor neuron disease involving both upper and lower motor neurons. We monitored HERV-K levels in plasma of 4 of these patients. RESULTS: Three patients who received antiretroviral therapy had reversal of symptoms within 6 months of onset of neurologic symptoms and the other 2 had slow neurologic progression over several years. Three patients in whom the levels were measured at onset of neurologic symptoms showed elevated HERV-K levels that responded to optimization of antiretroviral therapy for CNS penetration. CONCLUSIONS: Thus, motor neuron disease in individuals with HIV infection may a treatable entity, but early treatment with CNS-penetrating antiretroviral therapy may be necessary. Monitoring of HERV-K levels may help guide treatment.
OBJECTIVE: To determine whether there is activation of human endogenous retrovirus K (HERV-K) in amyotrophic lateral sclerosis in HIV infection and whether it might respond to treatment with antiretroviral drugs. METHODS: In this case series, we present 5 patients with HIV infection who subsequently developed motor neuron disease involving both upper and lower motor neurons. We monitored HERV-K levels in plasma of 4 of these patients. RESULTS: Three patients who received antiretroviral therapy had reversal of symptoms within 6 months of onset of neurologic symptoms and the other 2 had slow neurologic progression over several years. Three patients in whom the levels were measured at onset of neurologic symptoms showed elevated HERV-K levels that responded to optimization of antiretroviral therapy for CNS penetration. CONCLUSIONS: Thus, motor neuron disease in individuals with HIV infection may a treatable entity, but early treatment with CNS-penetrating antiretroviral therapy may be necessary. Monitoring of HERV-K levels may help guide treatment.
Authors: Marco Orsini; Marcos R G de Freitas; Julio G Silva; Márzia P Sohler; Carlos H M Reis; Antonio M da Silva Catharino; Acary B Oliveira; Sérgio Machado; Antonio E Nardi; Peter Salem; Flavio Sztajnbok; Marco A A Leite; Cristiane Nascimento; Eduardo Davidovich; Fábio H de Gobbi Porto; Márcia W Cruz; Sara L S de Menezes; Oscar Arias-Carrión Journal: Curr HIV Res Date: 2012-12 Impact factor: 1.581
Authors: G Galassi; M Gentilini; S Ferrari; G Ficarra; P Zonari; N Mongiardo; G Tommelleri; B Di Rienzo Journal: Clin Neuropathol Date: 1998 May-Jun Impact factor: 1.368
Authors: Adriana Carvalhal; M John Gill; Scott L Letendre; Anita Rachlis; Tsegaye Bekele; Janet Raboud; Ann Burchell; Sean B Rourke Journal: J Neurovirol Date: 2015-11-16 Impact factor: 2.643
Authors: Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis Journal: Arch Neurol Date: 2008-01
Authors: Laurie R Gray; Rachel E Jackson; Patrick E H Jackson; Stefan Bekiranov; David Rekosh; Marie-Louise Hammarskjöld Journal: Retrovirology Date: 2019-12-16 Impact factor: 4.602
Authors: Kiran T Thakur; Alexandra Boubour; Deanna Saylor; Mitashee Das; David R Bearden; Gretchen L Birbeck Journal: AIDS Date: 2019-02-01 Impact factor: 4.177
Authors: M Garcia-Montojo; S Fathi; G Norato; B R Smith; D B Rowe; M C Kiernan; S Vucic; S Mathers; R P A van Eijk; U Santamaria; M-L Rogers; A Malaspina; V Lombardi; P R Mehta; H-J Westeneng; L H van den Berg; A Al-Chalabi; J Gold; A Nath Journal: J Neurol Sci Date: 2021-02-23 Impact factor: 3.181
Authors: Domenico Di Curzio; Mamneet Gurm; Matthew Turnbull; Marie-Josée Nadeau; Breanna Meek; Julia D Rempel; Samuel Fineblit; Michael Jonasson; Sherry Hebert; Jennifer Ferguson-Parry; Renée N Douville Journal: Cells Date: 2020-06-30 Impact factor: 6.600